Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer.

ABSTRACT:

Background

The aim of this study was to assess homologous recombination deficiency (HRD) status and its correlation with carboplatin treatment response in early triple-negative breast cancer (TNBC) patients.

Methods

Tumor tissues from 225 consecutive TNBC patients were evaluated with an HRD panel and homologous recombination-related (HRR) gene expression data. HRD positivity was defined as a high HRD score and/or BRCA1/2 pathogenic or likely pathogenic mutation. Clinicopathological factors, neoadjuvant treatment response, and prognosis were analyzed with respect to HRD status in these TNBC patients.

Results

HRD positivity was found in 53.3% of patients and was significantly related to high Ki67 levels (P = 0.001). In patients who received neoadjuvant chemotherapy, HRD

SUBMITTER: Wang Z 

PROVIDER: S-EPMC11457550 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature